New treatment shows promise for rare neurological disorder
NCT ID NCT06193200
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This Phase 3 trial tested a treatment called EryDex for people with Ataxia Telangiectasia (A-T), a rare disease that affects movement and the immune system. The study involved 105 participants who received either EryDex or a placebo every 28 days. The goal was to see if EryDex could help control neurological symptoms like coordination problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATAXIA TELANGIECTASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Children's Hospital, Division of neurology
Cincinnati, Ohio, 45229, United States
-
Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology
Copenhagen, 2100, Denmark
-
Great Ormond Street Hospital for Children, Zayed Centre for Research
London, WC1N 1DZ, United Kingdom
-
Hospital Universitari Vall d'Hebron, Department of pediatric neurology
Barcelona, 08035, Spain
-
Hospital Universitario La Paz, Department of pediatric neurology
Madrid, 28046, Spain
-
IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases
Frankfurt, 60596, Germany
-
Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic
Warsaw, 04-736, Poland
-
MedPolonia sp zoo
Poznan, 60-693, Poland
-
Nottingham Children's Hospital, Queen's Medical Center, Children's neurology
Nottingham, NG7 2UH, United Kingdom
-
Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening
Oslo, 0372, Norway
-
Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health
Roma, 00161, Italy
-
Spedali Civili di Brescia, Pediatric immunology department
Brescia, 25123, Italy
-
St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection
London, SW17 0RE, United Kingdom
-
The Johns Hopkins Hospital, Division of pediatric allergy and immunology
Baltimore, Maryland, 21289, United States
-
UT Health Houston, Department of pediatrics, division of child & adolescent neurology
Houston, Texas, 77030, United States
-
University Children's Hospital Zürich - Eleonore Foundation
Zurich, CH-8008, Switzerland
-
University Hospital Frankfurt, Pediatric and Adolescent Clinic
Frankfurt, 60590, Germany
-
University Hospitals Birmingham NHS Foundation Trust
Birmingham, B152GW, United Kingdom
-
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.